Belite Bio, Inc (NasdaqCM: BLTE)
Health Care · Pharmaceuticals · US
$159.28
+3.10% today · +93.7% 1Y
Belite Bio, Inc (NasdaqCM: BLTE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.22B and employs 41 people.
Over the last twelve months the share price has gained 93.7%, trading between 77.64 and 200.00.
Tweenvest scores Belite Bio, Inc across four factors: quality 41/100, value 68/100. Its strongest factor is value.
BLTE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.22B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.74
- Dividend yield
- —
- Beta (5Y)
- -1.23
- 52-week high
- $200.00
- 52-week low
- $77.64
- Avg volume (3M)
- —
- Shares outstanding
- 40.27M
- Employees
- 41
- Next earnings
- —
About Belite Bio, Inc
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
- ISIN
- US07782B1044
- Founded
- 2016
- Listed since
- Apr 29, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| H. Lundbeck A/SCPSE: HLUN B | $6.76B | Dkr46.30 | +0.74% |
| Ono Pharmaceutical Co., Ltd.TSE: 4528 | $6.70B | ¥2,259.00 | +0.53% |
| Glenmark Pharmaceuticals LimitedNSEI: GLENMARK | $6.69B | Rs2,293.00 | -1.63% |
| Alkem Laboratories LimitedNSEI: ALKEM | $6.52B | Rs5,279.00 | +1.13% |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.SZSE: 000999 | $6.17B | CN¥24.82 | +1.39% |
| Ligand Pharmaceuticals IncorporatedNasdaqGM: LGND | $6.02B | $305.19 | +1.12% |
| Abbott India LimitedBSE: 500488 | $5.71B | Rs25,999.85 | -3.10% |
| Shanghai Allist Pharmaceuticals Co., Ltd.SHSE: 688578 | $5.54B | CN¥82.50 | -26.06% |
Figures last refreshed Oct 11, 2026.